Product Description: F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders[1].
Formula: C28H40N4O5S
References: [1]Dou X, et al. Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation. Eur J Med Chem. 2024;269:116323.
CAS Number: 1338190-14-9
Molecular Weight: 544.71
Research Area: Metabolic Disease
Solubility: 10 mM in DMSO
Target: Cytochrome P450;FXR;PPAR;RAR/RXR;ROR
English
Deutsch
